These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 23876612)
1. Duration of immunity to norovirus gastroenteritis. Simmons K; Gambhir M; Leon J; Lopman B Emerg Infect Dis; 2013 Aug; 19(8):1260-7. PubMed ID: 23876612 [TBL] [Abstract][Full Text] [Related]
2. The potential economic value of a human norovirus vaccine for the United States. Bartsch SM; Lopman BA; Hall AJ; Parashar UD; Lee BY Vaccine; 2012 Nov; 30(49):7097-104. PubMed ID: 23026689 [TBL] [Abstract][Full Text] [Related]
3. Noroviruses: epidemiology, immunity and prospects for prevention. Pringle K; Lopman B; Vega E; Vinje J; Parashar UD; Hall AJ Future Microbiol; 2015; 10(1):53-67. PubMed ID: 25598337 [TBL] [Abstract][Full Text] [Related]
4. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus. Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726 [TBL] [Abstract][Full Text] [Related]
5. Clinical profile of children with norovirus disease in rotavirus vaccine era. Wikswo ME; Desai R; Edwards KM; Staat MA; Szilagyi PG; Weinberg GA; Curns AT; Lopman B; Vinjé J; Parashar UD; Payne DC; Hall AJ Emerg Infect Dis; 2013 Oct; 19(10):1691-3. PubMed ID: 24047618 [No Abstract] [Full Text] [Related]
6. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642 [TBL] [Abstract][Full Text] [Related]
7. Norovirus Vaccine: Priorities for Future Research and Development. Esposito S; Principi N Front Immunol; 2020; 11():1383. PubMed ID: 32733458 [TBL] [Abstract][Full Text] [Related]
9. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control. Lopman BA; Steele D; Kirkwood CD; Parashar UD PLoS Med; 2016 Apr; 13(4):e1001999. PubMed ID: 27115709 [TBL] [Abstract][Full Text] [Related]
12. Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children. Payne DC; Parashar UD; Lopman BA Curr Opin Pediatr; 2015 Feb; 27(1):105-9. PubMed ID: 25490691 [TBL] [Abstract][Full Text] [Related]
13. Norovirus Infection: Replication, Manipulation of Host, and Interaction with the Host Immune Response. Sarvestani ST; Cotton B; Fritzlar S; O'Donnell TB; Mackenzie JM J Interferon Cytokine Res; 2016 Apr; 36(4):215-25. PubMed ID: 27046239 [TBL] [Abstract][Full Text] [Related]
14. Impact of genotype-specific herd immunity on the circulatory dynamism of norovirus: a 10-year longitudinal study of viral acute gastroenteritis. Sakon N; Yamazaki K; Nakata K; Kanbayashi D; Yoda T; Mantani M; Kase T; Takahashi K; Komano J J Infect Dis; 2015 Mar; 211(6):879-88. PubMed ID: 25210139 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in human norovirus research and implications for candidate vaccines. Cates JE; Vinjé J; Parashar U; Hall AJ Expert Rev Vaccines; 2020 Jun; 19(6):539-548. PubMed ID: 32500763 [TBL] [Abstract][Full Text] [Related]
16. New insights into the global burden of noroviruses and opportunities for prevention. Hall AJ; Glass RI; Parashar UD Expert Rev Vaccines; 2016 Aug; 15(8):949-51. PubMed ID: 27142965 [No Abstract] [Full Text] [Related]
17. Progress on norovirus vaccine research: public health considerations and future directions. Mattison CP; Cardemil CV; Hall AJ Expert Rev Vaccines; 2018 Sep; 17(9):773-784. PubMed ID: 30092671 [TBL] [Abstract][Full Text] [Related]
18. Norovirus vaccines under development. Lucero Y; Vidal R; O'Ryan G M Vaccine; 2018 Aug; 36(36):5435-5441. PubMed ID: 28668568 [TBL] [Abstract][Full Text] [Related]
19. Norovirus infections and seroprevalence of genotype GII.4-specific antibodies in a Spanish population. Carmona-Vicente N; Fernández-Jiménez M; Ribes JM; Téllez-Castillo CJ; Khodayar-Pardo P; Rodríguez-Diaz J; Buesa J J Med Virol; 2015 Apr; 87(4):675-82. PubMed ID: 25655810 [TBL] [Abstract][Full Text] [Related]
20. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Aliabadi N; Lopman BA; Parashar UD; Hall AJ Expert Rev Vaccines; 2015; 14(9):1241-53. PubMed ID: 26224658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]